Drug Profile
Research programme: HIV fusion inhibitors - Immunomedics/Karolinska Institute
Alternative Names: cP4/D10-(T20)4; h734-(T20)4; hLL2-(T20)4; IgG-(T20)4Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics; Karolinska Institute
- Class Immunoconjugates; Monoclonal antibodies; Peptides
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in Sweden (SC, Injection)
- 23 Jul 2012 Pharmacodynamics data from a preclinical trial in HIV-1 infections released by Karolinska Institute and Immunomedics